IXT-007

IXT-007 is an investigational inhalation therapy being developed by invoX Pharma, a subsidiary of Sino Biopharmaceutical. The drug is delivered using the proprietary Softhaler® platform, which is a propellant-free, breath-actuated device designed for efficient pulmonary delivery. While the Softhaler® technology is capable of delivering a variety of therapeutic modalities—including small molecules and complex biologics such as peptides, nucleic acids, and antibodies—the specific active ingredient, molecular target, and primary indication for IXT-007 have not been publicly disclosed. It is currently categorized in the early development stage of invoX Pharma's respiratory pipeline.